

TECH TOUR MEDTECH AWARD 2017

BIO



Jacques Essinger

Dr. Jacques Essinger was founder and CEO of Symetis for 12 years from 2005 till the acquisition by Boston Scientific in May 2017. He started his career as R&D director of a U.S. based CTscan image processing company, followed by co-founding and being the chief executive officer of Symbios Orthopedie in Yverdon, holding a general manager position of a U.S. based surgical tool company, and then becoming chief executive officer of Swiss based IsoTis Ortho Biologics, Inc, which he led from 1997 to 2004. During this time, he managed an initial public offering for the company on the Swiss stock exchange, as well as a merger of IsoTis Ortho Biologics, Inc and Gensci Orthobiology, Inc. Jacques Essinger holds a MS degree in Physics and a PhD degree in Biomechanics from the Swiss Federal Institute of Technology in Lausanne ("EPFL").

About Symetis

Symetis is the leading European developer of innovative, minimally invasive heart valve replacement devices. The company's products, ACURATE neo™ and ACURATE TA™ and their delivery systems, are based on proprietary design and delivery technologies, and marketed and sold in key markets in Europe and in other markets, and are well positioned to target the constantly growing TAVI market. Symetis is financed by a syndicate of blue chip venture capital firms. The company's headquarters are in Ecublens (Lausanne), Switzerland; its manufacturing sites are in Ecublens and Belo Horizonte, Brazil.